Connect with us

News

Round up: US$11m to accelerate breakthroughs in breast cancer research, world’s first whole-genome and transcriptome test, and more

Published

on

Femtech World explores the latest developments in business in the world of women’s health.

US$11m to accelerate breakthroughs in breast cancer research

Breast cancer organisation Susan G. Komen has announced today that it is awarding US$10.8m in new research grants to help propel innovation in breast cancer research.

The research grants will support 25 cutting-edge projects at 17 institutions.

Through this research investment, Komen is prioritising metastatic breast cancer, health inequities and the need for more precise, personalised treatment strategies to improve care and outcomes for everyone impacted by breast cancer.

So far, Komen’s 2025 research investment has seen 54 per cent of funding targets metastatic breast cancer, 50 per cent focused on precision medicine to tailor treatments to each patient’s unique biology, 21 per cent invested in addressing disparities to eliminate inequities in breast cancer care and outcomes, and 25 researchers funded, including 10 early-career investigators, representing the next generation of scientific leaders.

Juniper Genomics develops world’s first whole-genome and transcriptome test

Health tech company Juniper Genomics recently announced its public launch alongside a US$4.6m seed round.

Founded by experts in genomics, reproductive medicine, and bioethics, Juniper says its mission is to help patients shorten their IVF journey by offering more clarity and confidence on the first transfer.

Juniper’s proprietary platform combines whole genome and transcriptome sequencing with trio analysis, including both biological parents, to provide the most complete, clinically-relevant, and ethically responsible insights into each embryo’s health.

The single test replaces almost all existing forms of preimplantation genetic testing, and adds analysing thousands of clinically relevant genetic variants linked to IVF failure, miscarriage, and medical conditions after birth.

The test provides a clear, detailed and actionable view of embryo health and viability, screening for specific genetic changes known to cause adverse pregnancy outcomes and serious health conditions.

It is currently rolling out in early adopter clinics across North America.

Berry Fertility launches Smart Compose for patient support

Patient management platform for IVF, IUI, embryo transfer, and egg freezing, Berry Fertility, has announced the launch of its AI-powered Smart Compose tool for patient communications.

Smart Compose is designed to integrate seamlessly into existing workflows and EMRs, supporting care teams without disrupting their day-to-day operations, pulling relevant chart details, reviews patient messages, and references history to create a message draft that clinical staff can review and tweak before responding to patients.

According to the company, Smart Compose is purpose-built for the unique needs of fertility clinics and care teams, drawing on proprietary, vetted fertility content and a medication database developed by Berry Fertility.

Beyond EMR integration, Smart Compose can incorporate staff names, clinic locations, medication preferences, appointment calendars, and preferred educational materials to deliver the most accurate and relevant information.

And while Smart Compose adapts to each provider’s needs, their data remains isolated–ensuring that proprietary workflows are never shared or used to improve any other system. While it can understand patient data via workflow integrations, no AI models are trained on patient data. The result is innovative conversational technology, with safeguarded, secure guardrails.

Progyny adds pelvic floor therapy to its offerings

Women’s health company Progyny has announced that it has added digital pelvic floor therapy to its offering of women’s health solutions.

The therapy offers virtual and in-person support options for treatment and coaching, enabling earlier interventions for pelvic conditions and helping avoid delays that could lead to higher acuity treatments, surgeries, or increased healthcare costs for employers.

Progyny will be offering Origin and Hinge Health to its offering. With Origin, Progyny members can access Origin’s nationwide in-network pelvic floor physical therapy, providing evidence-based treatment for pelvic health needs including common concerns like leaky bladder, painful sex, and postpartum recovery, and more complex conditions including hysterectomy recovery, endometriosis, PCOS, and chronic pelvic pain.

With Hinge Health, members will receive digital care supported by physical therapists specialising in pelvic health and musculoskeletal (MSK) care.

Each individual will follow a personalised plan with guided exercises targeting their unique symptoms, including pelvic pain, a lack of pelvic strength or bladder control, and issues associated with menopause.

US$65m for at-home STI test

Diagnostics company Visby Medical recently raised approximately US$55m in its latest financing round.

According to the company, the funds will accelerate the launch and distribution of Visby Medical’s recently FDA-authorised at-home Women’s Sexual Health Test.

Catalio Capital Management, a leading innovative healthcare investment firm, will enhance Visby Medical’s market reach and operational capabilities. As part of the funding round, Catalio Partner Isaac Ro, will join Visby Medical’s board as an observer.

Chuck Alpuche, Chief Operating Officer at Imperative Care, former EVP and Chief Operating Officer at Insulet Corporation, and senior executive at PepsiCo, will also join Visby Medical’s board as an independent director.

According to Visby Medical, its at-home Women’s Sexual Health Test is the first single-use, disposable PCR diagnostic that delivers results within 30 minutes through a connected smartphone app.

Upon receiving positive results, users are connected with telemedicine providers for consultation and treatment, enhancing healthcare accessibility and privacy. The product will be available starting July 2025 through major direct-to-consumer channels.

Gates Foundations awards US$1.9m for preeclampsia treatment

Beech Biotech has received a grant of US$1.9m from the Bill and Melinda Gates Foundation to advance its preeclampsia treatment.

The company is developing “mother only” monoclonals to treat complications of pregnancy, and, according to Beech Biotech, its lead asset – MOm303 – binds and eliminates maternal sFlt-1, targeting a key driver of disease pathology.

The company has said that the funding will help advance the asset for IND-approval.

€4.5m raised for pelvic organ prolapse device

Medical device company Escala Medical has been granted €4.5m to support commercialisation activities for Medit – the company’s pelvic organ prolapse device.

The FDA-cleared device enables the restoration of pelvic floor function within 10 minutes using an incision-free, outpatient procedure.

The funds were awarded from the European Innovation Council (EIC) and other investors.

According to the company, the funds will support expansion into Europe and further international growth in Southeast Asia.

Pregnancy

Pregnant women may reduce key health risk through more light exercise, study finds

Published

on

Light exercise and less sitting may reduce pregnant women’s risk of serious blood pressure complications, according to a new study.

Researchers have proposed a daily activity and sleep guide that they say was linked to a nearly 30 per cent lower risk of hypertensive disorders of pregnancy.

The suggested pattern includes fewer than eight hours of sedentary time, at least seven hours of light physical activity, around 22 minutes of more intense activity and nearly nine hours of sleep.

The University of Iowa-led study examined the daily behaviours of 470 pregnant women across all stages of pregnancy.

Participants wore monitors that measured physical activity over 24-hour periods and recorded how long they spent asleep.

Hypertensive disorders of pregnancy include chronic high blood pressure, gestational hypertension and pre-eclampsia.

Gestational hypertension is high blood pressure that develops during pregnancy, while pre-eclampsia is a potentially serious condition involving high blood pressure and signs that organs may be affected.

Sedentary behaviour means being mostly inactive, such as sitting or lying down.

Light physical activity can include casual walking, moving around the home or standing.

Moderate to vigorous activity includes movement such as brisk walking, where breathing and heart rate increase.

Kara Whitaker, associate professor in the department of health, sport, and human physiology at Iowa and corresponding author of the study, said: “We are identifying the optimal composition of movement behaviours across the day associated with the lowest risk of developing HDP and the most improved health outcomes.

“This blueprint holds for each and every trimester of pregnancy.”

Study participants were enrolled at sites in Iowa City, Pittsburgh and Morgantown, West Virginia.

The women wore activity and sleep monitors for at least one week during each trimester of pregnancy.

Four in five participants were non-Hispanic white and nearly a quarter lived in rural areas.

The data showed a steep rise in risk among pregnant women who were sedentary for more than 10 hours a day.

Women who increased light physical activity to at least four hours a day reduced their risk of hypertensive disorders of pregnancy to 15 per cent from 30 per cent.

Whitaker said: “Just moving around more seems to have significant health benefits.

“And I think it also may be a more feasible target for women who are pregnant who are not exercising regularly.”

The researchers said they were surprised that longer durations of moderate to vigorous physical activity did not appear to provide additional benefit.

Sleep beyond a certain duration also did not appear to bring major further benefits.

Whitaker said: “Through this study, we are providing evidence that reducing sedentary behaviour and engaging in light physical activity are important, and maybe more important, when it comes to pregnancy and health.”

The findings may be relevant beyond pregnancy because clinical research has shown that women who develop hypertensive disorders of pregnancy are more than twice as likely to develop heart disease later in life.

Cardiovascular disease includes conditions affecting the heart and blood vessels, such as heart disease and stroke.

Whitaker said: “We know that cardiovascular disease is the number one killer of women, and if we can intervene in pregnancy and prevent women from developing a hypertensive disorder of pregnancy, we are putting them on a better trajectory, away from cardiovascular disease and toward more optimal cardiovascular health.”

The study was published online on June 10.

A second study, published online on May 27, looked more closely at the ratio and type of sedentary behaviour and light physical activity linked to a lower risk of hypertensive disorders of pregnancy.

Whitaker is a lead co-author on that study.

Co-authors in the June 10 study include Alex Crisp, Jaemyung Kim, Karina Smith, Donna Santillan, Mark Santillan and Bridget Zimmerman, from Iowa; Jacob Gallagher, from Iowa State University; Melissa Jones, from Oakland University in Michigan; Bethany Barone Gibbs, Katrina Wilhite, Alexis Thrower and Iqra Sheikh, from West Virginia University; and Sabera Rahman, Janet Catov, Christopher Kline and Maisa Feghali, from the University of Pittsburgh.

The National Institutes of Health, the University of Iowa Institute for Clinical and Translational Science, the University of Pittsburgh Clinical and Translational Science Institute and the West Virginia Clinical and Translational Science Institute funded the research.

Continue Reading

News

Femtech World Awards 2026: Winners revealed

Published

on

We are excited to reveal the winners of the third annual Femtech World Awards.

The winners were announced at a virtual event this afternoon attended by shortlisted companies, along with sponsors and judges.

The event welcomed guests from the UK, Europe, Asia, Africa and North America.

Thank you to all 174 entries, as well as the sponsors for making the event possible.

See you in 2027!

Femtech World Awards 2026 Winners

Winner:

Shortlisted:

IVI RMA x Juno Genetics

Natural Cycles

Winner:

Highly commended:

U-Ploid

Shortlisted:

Hello Inside

Winner:

WISE HF, led by Prof. Mary Ryder

Highly commended:

Cardiac College for Women

Shortlisted:

Hyvelle Ferguson-Davis

CognitiveCare

Winner:

Highly commended:

Youterus

Shortlisted:

ŌURA

Winner:

Shortlisted:

LeanShield by ParrotPal Group

Perigen

Winner:

Shortlisted:

Body Moody

Looop

Winner:

Shortlisted:

Owning Your Menopause

Womeno

Winner:

Shortlisted:

The Blue Box

Celbrea

Winner:

Shortlisted:

HealCycle

Mor

Winner:

Shortlisted:

HRC Fertility

Mira

Continue Reading

Motherhood

Expectations about sleep affect postpartum sleep quality, study finds

Published

on

Pregnant women’s expectations about postpartum sleep may predict sleep quality after birth, outweighing prior sleep and psychiatric history, a study suggests.

The findings suggest attitudes and beliefs about sleep during pregnancy could be a modifiable risk factor for postpartum sleep concerns.

They also indicate that, among women expecting the poorest sleep, higher postpartum anxiety may further worsen sleep quality.

Sammy Dhaliwal, lead author is clinical health psychologist and research fellow in the department of obstetrics and gynaecology at the Perelman School of Medicine at the University of Pennsylvania.

Dhaliwal said: “Most pregnant women in our sample anticipated poor postpartum sleep before it occurred, and it was striking that those expectations predicted worse sleep outcomes even after accounting for factors such as prior sleep disorders, psychiatric history, and number of previous births.

“This suggests that attitudes and beliefs about sleep during pregnancy may represent a modifiable target for early intervention before postpartum sleep problems emerge.”

Sleep disturbance affects an estimated 60 to 80 per cent of postpartum women and is linked to a higher risk of depression and anxiety.

Researchers said it is often regarded as an expected part of life after childbirth rather than a health issue that may be addressed earlier.

The study enrolled 432 pregnant women at about 24 weeks of gestation, meaning around 24 weeks into pregnancy.

Participants completed measures of their expectations about postpartum sleep, current sleep quality using the Pittsburgh Sleep Quality Index, and mood using validated depression and anxiety scales.

Assessments were repeated at six, 12 and 24 weeks postpartum.

A subset of 49 women also wore wrist actigraphy devices at six to eight weeks postpartum.

Actigraphy uses a wearable device, similar to a watch, to estimate sleep and wake patterns based on movement.

The results showed that 70 per cent of pregnant women, or 301 of 432 participants, expected poor sleep in the postpartum period.

Researchers found that predicted sleep disruption during pregnancy was a significant predictor of postpartum sleep concerns.

Among first-time pregnant women without prior health concerns, those who expected greater sleep disturbance had significantly more disrupted sleep after birth, measured by both actigraphy and self-report.

Among women who expected the worst sleep quality, higher postpartum anxiety significantly worsened both measured sleep and self-reported sleep, independent of anxiety levels during pregnancy.

Dhaliwal said the findings point to two possible areas for intervention: addressing sleep-related beliefs during pregnancy and treating postpartum anxiety.

Dhaliwal said: “Postpartum sleep disruption is often treated only after problems develop, but our findings suggest there may be an opportunity to intervene earlier during pregnancy.

“Addressing sleep-related beliefs and postpartum anxiety during prenatal and postpartum care may help improve sleep and emotional well-being in new mothers.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.